Indivior

The world leader in addiction treatment with 20 years of experience and a unique, patient-focused approach. We didn’t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They’re often unaware of their treatment options, have limited access to treatment, or simply don’t seek it out because they’re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, policymakers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like sufferers other chronic diseases. The past two decades have been marked by strong growth and an expansion into more than 40 countries. While opioid dependence marketplace has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance opioid dependence treatment and combat broader addiction epidemics including opiate overdose, alcohol use disorders, cocaine intoxication and schizophrenia by bringing to market novel treatment solutions worldwide.
Type
Public
HQ
Slough, GB
Employees
831 (est)+13%

Indivior Locations

Slough, GB
Cleveland, US
Baltimore, US
Phoenix, US
Ottawa, CA
Mannheim, DE
Milano, IT
Massy, FR
Beijing, CN
Richmond, US
New Haven, US
Dayton, US
Fort Collins, US
Chicago, US

Indivior Metrics

Indivior Summary

Market capitalization

£2.3 B

Closing share price

£3.18

Indivior Financials

FY, 2013FY, 2014FY, 2015

Revenue

£800 M£763 M£694 M

Revenue growth, %

-4.6%-9.1%

Cost of sales

£68.4 M£65 M£66.4 M

Gross profit

£731 M£698 M£627 M

Gross profit Margin, %

91.4%91.5%90.4%

Operating expense total

£274 M£313 M£391 M

Indivior Market Value History

Indivior News

Indivior Company Life